Home » Authors » Jim Shrine

Articles by Jim Shrine

TransOral Reports Positive Data From Phase III Trial In Insomnia

June 18, 2007

TransOral Reports Positive Data From Phase III Trial In Insomnia

June 18, 2007

Par Pharmaceutical Gains Rights To Phase III Drug From Immtech

June 13, 2007

Par Pharmaceutical Cos. Inc. gained exclusive rights in the U.S. to a Phase III drug from Immtech Pharmaceuticals Inc. for treating pneumocystis pneumonia in AIDS patients. (BioWorld Today)

Par Pharmaceutical Gains Rights To Phase III Drug From Immtech

June 13, 2007

Par Pharmaceutical Cos. Inc. gained exclusive rights in the U.S. to a Phase III drug from Immtech Pharmaceuticals Inc. for treating pneumocystis pneumonia in AIDS patients. (BioWorld Today)

NeurogesX presents positive data from trial of pain patch

June 11, 2007

NeurogesX Presents Positive Data From Trial Of Pain Patch

June 8, 2007

NewCo News: Aileron Raises $7M For Work On Peptide Technology Platform

June 7, 2007

Response Genetics Raises $21M In IPO For Pharmacogenomics

June 6, 2007

Response Genetics Raises $21M In IPO For Pharmacogenomics

June 6, 2007

Labopharm Falls 50 Percent On Second FDA Approvable Letter

June 4, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...